1164. Influenza Clinical Diagnostic Testing and Antiviral Treatment among Children Hospitalized with Acute Respiratory Illness during the 2015-16 Influenza Season
Session: Poster Abstract Session: Diagnostics: Viral
Friday, October 6, 2017
Room: Poster Hall CD

Background:  Although antiviral therapy is recommended for hospitalized patients with suspected or confirmed influenza, clinicians often rely on test results to determine management. Rapid influenza diagnostic tests (RIDTs) have suboptimal sensitivity; use of molecular assays may improve care. We evaluated clinical influenza testing and antiviral treatment practices in hospitalized children.

Methods:  Children aged <18 years with acute respiratory illness (ARI) were enrolled through active surveillance at 7 hospitals in the New Vaccine Surveillance Network between 11/1/15 and 6/30/16; analysis was restricted to the influenza season. Preliminary data were analyzed for children who had clinical influenza diagnostic testing with a rapid influenza diagnostic test or molecular assay on nasopharyngeal or nasal swabs or nasal washes. Children who had received antivirals prior to hospitalization were excluded.

Results:  Of 2267 children, 1165 (51%) had clinical diagnostic testing on upper respiratory samples: 276 (24%) by RIDT alone, 780 (67%) by molecular testing alone, and 109 (9%) by both. Use of molecular testing alone varied by site, from 10% to 100% of samples tested. Of 116 (10%) children testing positive for influenza, 60 (52%) were treated; by site, treatment of children positive for influenza ranged from 25% to 83%. Antiviral treatment was given to 16/20 (80%) of those admitted ≤2 days from symptom onset vs 44/96 (46%) children admitted >2 days after onset. Among 94 children tested by one method who were positive, >80% had samples collected in the emergency department or on day of admission, and 47 started treatment (Figure, A): 16/37 (43%) and 31/57 (54%) were treated when tested by RIDT alone and molecular testing alone, respectively. Of those positive children treated, 7/16 (44%) tested by RIDT vs 22/31 (71%) by molecular testing started treatment on the day of testing (Figure, B).

Conclusion: Half of hospitalized children with ARI who tested positive for influenza received antiviral treatment. Although there was high variability in testing and treatment by site, in positive patients who were treated use of molecular testing appeared to be associated with prompt antiviral therapy. Understanding clinician reasons for relatively low treatment overall will require further investigation.

Angela P. Campbell, MD, MPH, FPIDS, FIDSA1, Craig McGowan, MS1, Brian Rha, MD, MSPH2, Julie A. Boom, MD3, Janet Englund, MD, FIDSA4, Natasha B. Halasa, MD, MPH, FPIDS5, Rangaraj Selvarangan, PhD6, Mary A. Staat, M.D., M.P.H.7, Geoffrey A. Weinberg, MD, FIDSA, FPIDS8, Parvin H. Azimi, MD9, Eileen J. Klein, MD, MPH4, Monica McNeal, MS7, Leila C. Sahni, MPH3, Monica N. Singer, MD, MPH10, Laura Stewart, PhD11, Peter G. Szilagyi, MD, MPH8,12, Christopher J. Harrison, M.D., FAAP, FPIDS13, Daniel C. Payne, PhD, MSPH14 and Alicia M. Fry, MD, MPH1, (1)Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, (2)Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, (3)Texas Children's Hospital, Houston, TX, (4)University of Washington/Seattle Children's Hospital, Seattle, WA, (5)Vanderbilt University School of Medicine, Nashville, TN, (6)Microbiology Laboratory, Children's Mercy Hospital and Clinics, Kansas City, MO, (7)Cincinnati Children's Hospital Medical Center, Cincinnati, OH, (8)Univ. of Rochester Sch. of Medicine and Dentistry, Rochester, NY, (9)UCSF Benioff Children's Hospital Oakland, Oakland, CA, (10)UCSF Benioff Children’s Hospital Oakland, Oakland, CA, (11)Vanderbilt University Medical Center, Nashville, TN, (12)University of California at Los Angeles, Los Angeles, CA, (13)Children's Mercy Hospital and Clinics, Kansas City, MO, (14)Centers for Disease Control and Prevention, Atlanta, GA


A. P. Campbell, None

C. McGowan, None

B. Rha, None

J. A. Boom, None

J. Englund, Gilead: Consultant and Investigator , Research support
Chimerix: Investigator , Research support
Alios: Investigator , Research support
Novavax: Investigator , Research support
MedImmune: Investigator , Research support
GlaxoSmithKline: Investigator , Research support

N. B. Halasa, Sanofi Pasteur: Research Contractor , Research support
Astra Zeneca: Research Contractor , Grant recipient

R. Selvarangan, None

M. A. Staat, None

G. A. Weinberg, None

P. H. Azimi, None

E. J. Klein, None

M. McNeal, None

L. C. Sahni, None

M. N. Singer, None

L. Stewart, None

P. G. Szilagyi, None

C. J. Harrison, None

D. C. Payne, None

A. M. Fry, None

See more of: Diagnostics: Viral
See more of: Poster Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.